[{"id":"68ee80d7-4df8-4d6d-b5f5-3f61a898eb3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02783599","created_at":"2021-01-18T13:39:19.516Z","updated_at":"2024-07-02T16:36:57.053Z","phase":"Phase 1b","brief_title":"A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02783599","lead_sponsor":"Eli Lilly and Company","biomarkers":" PDGFRA • PDGFC","pipe":" | ","alterations":" PDGFRA expression","tags":["PDGFRA • PDGFC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • Lartruvo (olaratumab)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 10/11/2016","start_date":" 10/11/2016","primary_txt":" Primary completion: 07/05/2018","primary_completion_date":" 07/05/2018","study_txt":" Completion: 07/05/2018","study_completion_date":" 07/05/2018","last_update_posted":"2019-08-12"}]